Haleon (LON:HLN) Earns “Buy” Rating from Jefferies Financial Group

Haleon (LON:HLN)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Financial Group in a report issued on Friday, Digital Look reports. They currently have a GBX 400 price target on the stock. Jefferies Financial Group‘s target price would suggest a potential upside of 23.53% from the company’s current price.

HLN has been the subject of a number of other reports. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Haleon from GBX 335 to GBX 320 and set a “sell” rating for the company in a report on Wednesday, September 9th. Royal Bank Of Canada increased their price target on Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research report on Tuesday, August 11th. Finally, Berenberg Bank raised their price objective on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of GBX 385.80.

Haleon Price Performance

Shares of HLN stock traded up GBX 6.10 on Friday, hitting GBX 323.80. 1,049,375,500 shares of the company’s stock were exchanged, compared to its average volume of 32,993,621. The stock has a market cap of £28.48 billion, a P/E ratio of 17.89, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a debt-to-equity ratio of 50.38, a current ratio of 0.69 and a quick ratio of 0.93. The company has a 50 day moving average of GBX 353.77 and a 200 day moving average of GBX 360.62. Haleon has a 12 month low of GBX 310.50 and a 12 month high of GBX 433.60.

Haleon (LON:HLN) last posted its earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. On average, equities research analysts predict that Haleon will post 19.50 EPS for the current year.

Haleon declared that its board has approved a stock buyback program on Thursday, October 29th that allows the company to repurchase £500 million in shares. This repurchase authorization allows the company to reacquire up to 1.8% of its stock through open market purchases. Share repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Haleon News Roundup

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon approved a £500 million share repurchase programme, allowing it to buy back up to 1.8% of outstanding shares through open-market purchases. The authorization may support earnings per share and signals management’s view that the stock is undervalued. Haleon Q3 Revenue Rises; Trims Annual Revenue Growth Outlook; Launches £500 Mln Share Buyback
• Neutral Sentiment: Management maintained its profit outlook while launching the repurchase plan, which could limit the earnings impact of softer sales. However, the buyback is primarily a capital-return measure and does not resolve the company’s near-term growth challenges. Haleon Launches £500m Share Buyback to Cut Capital and Support Employee Plans
• Negative Sentiment: Third-quarter organic revenue growth was 2.6%, below expectations, prompting Haleon to cut its 2026 organic growth forecast to about 2.5% from the previous 3%–5% range. The downgrade is the main reason the stock declined sharply. Haleon drops after Q3 sales miss and lower 2026 growth outlook
• Negative Sentiment: Haleon cited weaker cough, cold and flu consumption in North America, disruption to OTC-registered Centrum products in China, and an expected fourth-quarter revenue hit from an accelerated go-to-market change in Brazil. These issues raise concerns about uneven demand and execution across key markets. Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.